ScholarLens Back to search
2005•Journal watchRequires access

When Should Aromatase Inhibitors Be Used as Adjuvant Therapy for Breast Cancer

Christine D. Berg

Open publisher page 0 citations

Abstract

Aromatase inhibitors, which block estrogen synthesis, are promising agents for the treatment of postmenopausal breast cancer in both metastatic and

About this research paper

What this paper is about

Aromatase inhibitors, which block estrogen synthesis, are promising agents for the treatment of postmenopausal breast cancer in both metastatic and

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Aromatase inhibitors, which block estrogen synthesis, are promising agents for the treatment of postmenopausal breast cancer in both metastatic and

Key concepts: Medicine, Aromatase, Breast cancer, Oncology, Adjuvant, Internal medicine, Adjuvant therapy, Aromatase inhibitor

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
When Should Aromatase Inhibitors Be Used as Adjuvant Therapy for Breast Cancer — Research Paper | ScholarLens